{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:22:45Z","timestamp":1791958965065,"version":"4.3.4"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,2]]},"DOI":"10.7759\/cureus.27622","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T02:04:17Z","timestamp":1659492257000},"source":"Crossref","is-referenced-by-count":7,"title":["The Efficacy and Safety of Pimecrolimus in Patients With Facial Seborrheic Dermatitis: A Systematic Review of Randomized Controlled Trials"],"prefix":"10.7759","author":[{"given":"Odeh","family":"Alsmeirat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Som","family":"Lakhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musab","family":"Egaimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Idris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Elkhalifa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03779.x","article-title":"Malassezia globosa as the causative agent of pityriasis versicolor","volume":"143","author":"Crespo Erchiga V","year":"2000","unstructured":"Crespo Erchiga V, Ojeda Martos A, Vera Casa\u00f1o A, Crespo Erchiga A, Sanchez Fajardo F. Malassezia globosa as the causative agent of pityriasis versicolor. Br J Dermatol. 2000, 143:799-803. 10.1046\/j.1365-2133.2000.03779.x","journal-title":"Br J Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.13188\/2373-1044.1000019","article-title":"Seborrheic dermatitis and dandruff: a comprehensive review","volume":"3","author":"Borda LJ","year":"2015","unstructured":"Borda LJ, Wikramanayake TC. Seborrheic dermatitis and dandruff: a comprehensive review. J Clin Investig Dermatol. 2015, 3:10.13188\/2373-1044.1000019","journal-title":"J Clin Investig Dermatol"},{"key":"ref3","article-title":"Adult seborrheic dermatitis: a status report on practical topical management","volume":"4","author":"Del Rosso JQ","year":"2011","unstructured":"Del Rosso JQ. Adult seborrheic dermatitis: a status report on practical topical management. J Clin Aesthet Dermatol. 2011, 4:32-8.","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/s0733-8635(03)00028-7","article-title":"Seborrheic dermatitis","volume":"21","author":"Gupta AK","year":"2003","unstructured":"Gupta AK, Bluhm R, Cooper EA, Summerbell RC, Batra R. Seborrheic dermatitis. Dermatol Clin. 2003, 21:401-12. 10.1016\/s0733-8635(03)00028-7","journal-title":"Dermatol Clin"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15908","article-title":"Prevalence and determinants of seborrhoeic dermatitis in a middle-aged and elderly population: the Rotterdam Study","volume":"178","author":"Sanders MG","year":"2018","unstructured":"Sanders MG, Pardo LM, Franco OH, Ginger RS, Nijsten T. Prevalence and determinants of seborrhoeic dermatitis in a middle-aged and elderly population: the Rotterdam Study. Br J Dermatol. 2018, 178:148-53. 10.1111\/bjd.15908","journal-title":"Br J Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4103\/0974-7753.82117","article-title":"A new postulate on two stages of dandruff: a clinical perspective","volume":"3","author":"Manuel F","year":"2011","unstructured":"Manuel F, Ranganathan S. A new postulate on two stages of dandruff: a clinical perspective. Int J Trichology. 2011, 3:3-6. 10.4103\/0974-7753.82117","journal-title":"Int J Trichology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/s0190-9622(88)70175-9","article-title":"Cutaneous manifestations of early human immunodeficiency virus exposure","volume":"19","author":"Berger RS","year":"1988","unstructured":"Berger RS, Stoner MF, Hobbs ER, Hayes TJ, Boswell RN. Cutaneous manifestations of early human immunodeficiency virus exposure. J Am Acad Dermatol. 1988, 19:298-303. 10.1016\/s0190-9622(88)70175-9","journal-title":"J Am Acad Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/s0190-9622(86)70028-5","article-title":"Seborrheic-like dermatitis of acquired immunodeficiency syndrome","volume":"14","author":"Soeprono FF","year":"1986","unstructured":"Soeprono FF, Schinella RA, Cockerell CJ, Comite SL. Seborrheic-like dermatitis of acquired immunodeficiency syndrome. J Am Acad Dermatol. 1986, 14:242-8. 10.1016\/s0190-9622(86)70028-5","journal-title":"J Am Acad Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12682040","article-title":"Sebaceous gland secretion in Parkinson's disease during L-dopa treatment","volume":"60","author":"Kohn SR","year":"1973","unstructured":"Kohn SR, Pochi PE, Strauss JS, Sax DS, Feldman RG, Timberlake WH. Sebaceous gland secretion in Parkinson's disease during L-dopa treatment. J Invest Dermatol. 1973, 60:134-6. 10.1111\/1523-1747.ep12682040","journal-title":"J Invest Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1731","article-title":"Quality of life assessment of patients with scalp dermatitis using the Italian version of the Scalpdex","volume":"94","author":"Sampogna F","year":"2014","unstructured":"Sampogna F, Linder D, Piaserico S, et al.. Quality of life assessment of patients with scalp dermatitis using the Italian version of the Scalpdex. Acta Derm Venereol. 2014, 94:411-4. 10.2340\/00015555-1731","journal-title":"Acta Derm Venereol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.05.048","article-title":"The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology","volume":"55","author":"Bickers DR","year":"2006","unstructured":"Bickers DR, Lim HW, Margolis D, et al.. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol. 2006, 55:490-500. 10.1016\/j.jaad.2006.05.048","journal-title":"J Am Acad Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1382","article-title":"A comprehensive pathophysiology of dandruff and seborrheic dermatitis - towards a more precise definition of scalp health","volume":"93","author":"Schwartz JR","year":"2013","unstructured":"Schwartz JR, Messenger AG, Tosti A, et al.. A comprehensive pathophysiology of dandruff and seborrheic dermatitis - towards a more precise definition of scalp health. Acta Derm Venereol. 2013, 93:131-7. 10.2340\/00015555-1382","journal-title":"Acta Derm Venereol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/9781444300161","article-title":"Evidence-Based Dermatology, 2nd ed","year":"2008","unstructured":"Evidence-Based Dermatology, 2nd ed. Williams H, Bigby M, Diepgen T, Herxheimer A, Naldi L, Rzany B (ed). John Wiley & Sons, Hoboken, New Jersey, United States; 2008. 10.1002\/9781444300161"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/mmy.39.3.243.251","article-title":"Quantitative culture of Malassezia species from different body sites of individuals with or without dermatoses","volume":"39","author":"Gupta AK","year":"2001","unstructured":"Gupta AK, Kohli Y, Summerbell RC, Faergemann J. Quantitative culture of Malassezia species from different body sites of individuals with or without dermatoses. Med Mycol. 2001, 39:243-51. 10.1080\/mmy.39.3.243.251","journal-title":"Med Mycol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1993.tb00480.x","article-title":"The carriage of Malassezia furfur serovars A, B and C in patients with pityriasis versicolor, seborrhoeic dermatitis and controls","volume":"129","author":"Ashbee HR","year":"1993","unstructured":"Ashbee HR, Ingham E, Holland KT, Cunliffe WJ. The carriage of Malassezia furfur serovars A, B and C in patients with pityriasis versicolor, seborrhoeic dermatitis and controls. Br J Dermatol. 1993, 129:533-40. 10.1111\/j.1365-2133.1993.tb00480.x","journal-title":"Br J Dermatol"},{"key":"ref16","article-title":"Seborrheic dermatitis and Malassezia species: how are they related?","volume":"2","author":"Kim GK","year":"2009","unstructured":"Kim GK. Seborrheic dermatitis and Malassezia species: how are they related?. J Clin Aesthet Dermatol. 2009, 2:14-7.","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1258\/002367787781363336","article-title":"Inherited seborrheic dermatitis--a new mutant in mice","volume":"21","author":"H\u00f6ger H","year":"1987","unstructured":"H\u00f6ger H, Gialamas J, Adamiker D. Inherited seborrheic dermatitis--a new mutant in mice. Lab Anim. 1987, 21:299-305. 10.1258\/002367787781363336","journal-title":"Lab Anim"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1258\/002367794780745100","article-title":"Reduced tumour incidence in mice with inherited seborrhoeic dermatitis","volume":"28","author":"H\u00f6ger H","year":"1994","unstructured":"H\u00f6ger H, Gialamas J, Adamiker D. Reduced tumour incidence in mice with inherited seborrhoeic dermatitis. Lab Anim. 1994, 28:340-6. 10.1258\/002367794780745100","journal-title":"Lab Anim"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2004.23565.x","article-title":"A novel T cell receptor transgenic animal model of seborrheic dermatitis-like skin disease","volume":"124","author":"Oble DA","year":"2005","unstructured":"Oble DA, Collett E, Hsieh M, Ambj\u00f8rn M, Law J, Dutz J, Teh HS. A novel T cell receptor transgenic animal model of seborrheic dermatitis-like skin disease. J Invest Dermatol. 2005, 124:151-9. 10.1111\/j.0022-202X.2004.23565.x","journal-title":"J Invest Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04082.x","article-title":"Seborrhoeic dermatitis and Pityrosporum (Malassezia) folliculitis: characterization of inflammatory cells and mediators in the skin by immunohistochemistry","volume":"144","author":"Faergemann J","year":"2001","unstructured":"Faergemann J, Bergbrant IM, Dohs\u00e9 M, Scott A, Westgate G. Seborrhoeic dermatitis and Pityrosporum (Malassezia) folliculitis: characterization of inflammatory cells and mediators in the skin by immunohistochemistry. Br J Dermatol. 2001, 144:549-56. 10.1046\/j.1365-2133.2001.04082.x","journal-title":"Br J Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2494.2012.00723.x","article-title":"Stratum corneum dysfunction in dandruff","volume":"34","author":"Turner GA","year":"2012","unstructured":"Turner GA, Hoptroff M, Harding CR. Stratum corneum dysfunction in dandruff. Int J Cosmet Sci. 2012, 34:298-306. 10.1111\/j.1468-2494.2012.00723.x","journal-title":"Int J Cosmet Sci"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.117849","article-title":"Dandruff has an altered stratum corneum ultrastructure that is improved with zinc pyrithione shampoo","volume":"45","author":"Warner RR","year":"2001","unstructured":"Warner RR, Schwartz JR, Boissy Y, Dawson TL Jr. Dandruff has an altered stratum corneum ultrastructure that is improved with zinc pyrithione shampoo. J Am Acad Dermatol. 2001, 45:897-903. 10.1067\/mjd.2001.117849","journal-title":"J Am Acad Dermatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08578.x","article-title":"Alterations in the desquamation-related proteolytic cleavage of corneodesmosin and other corneodesmosomal proteins in psoriatic lesional epidermis","volume":"159","author":"Simon M","year":"2008","unstructured":"Simon M, Tazi-Ahnini R, Jonca N, Caubet C, Cork MJ, Serre G. Alterations in the desquamation-related proteolytic cleavage of corneodesmosin and other corneodesmosomal proteins in psoriatic lesional epidermis. Br J Dermatol. 2008, 159:77-85. 10.1111\/j.1365-2133.2008.08578.x","journal-title":"Br J Dermatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1087-0024.2005.10119.x","article-title":"Three etiologic facets of dandruff and seborrheic dermatitis: Malassezia fungi, sebaceous lipids, and individual sensitivity","volume":"10","author":"DeAngelis YM","year":"2005","unstructured":"DeAngelis YM, Gemmer CM, Kaczvinsky JR, Kenneally DC, Schwartz JR, Dawson TL Jr. Three etiologic facets of dandruff and seborrheic dermatitis: Malassezia fungi, sebaceous lipids, and individual sensitivity. J Investig Dermatol Symp Proc. 2005, 10:295-7. 10.1111\/j.1087-0024.2005.10119.x","journal-title":"J Investig Dermatol Symp Proc"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/ng1813","article-title":"Seborrhea-like dermatitis with psoriasiform elements caused by a mutation in ZNF750, encoding a putative C2H2 zinc finger protein","volume":"38","author":"Birnbaum RY","year":"2006","unstructured":"Birnbaum RY, Zvulunov A, Hallel-Halevy D, et al.. Seborrhea-like dermatitis with psoriasiform elements caused by a mutation in ZNF750, encoding a putative C2H2 zinc finger protein. Nat Genet. 2006, 38:749-51. 10.1038\/ng1813","journal-title":"Nat Genet"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2010.04629.x","article-title":"Epidermal changes associated with symptomatic resolution of dandruff: biomarkers of scalp health","volume":"50","author":"Kerr K","year":"2011","unstructured":"Kerr K, Darcy T, Henry J, et al.. Epidermal changes associated with symptomatic resolution of dandruff: biomarkers of scalp health. Int J Dermatol. 2011, 50:102-13. 10.1111\/j.1365-4632.2010.04629.x","journal-title":"Int J Dermatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2013.01.001","article-title":"Seborrheic dermatitis: etiology, risk factors, and treatments: facts and controversies","volume":"31","author":"Dessinioti C","year":"2013","unstructured":"Dessinioti C, Katsambas A. Seborrheic dermatitis: etiology, risk factors, and treatments: facts and controversies. Clin Dermatol. 2013, 31:343-51. 10.1016\/j.clindermatol.2013.01.001","journal-title":"Clin Dermatol"},{"key":"ref28","article-title":"Seborrheic dermatitis: an update","volume":"20","author":"Bukvi\u0107 Mokos Z","year":"2012","unstructured":"Bukvi\u0107 Mokos Z, Kralj M, Basta-Juzba\u0161i\u0107 A, Lako\u0161 Juki\u0107 I. Seborrheic dermatitis: an update. Acta Dermatovenerol Croat. 2012, 20:98-104.","journal-title":"Acta Dermatovenerol Croat"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(70)92476-1","article-title":"Effect of L-dopa on seborrhoea of parkinsonism","volume":"2","author":"Burton JL","year":"1970","unstructured":"Burton JL, Shuster S. Effect of L-dopa on seborrhoea of parkinsonism. Lancet. 1970, 2:19-20. 10.1016\/s0140-6736(70)92476-1","journal-title":"Lancet"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1973.tb15453.x","article-title":"Effect of L-dopa on the seborrhoea of Parkinsonism","volume":"88","author":"Burton JL","year":"1973","unstructured":"Burton JL, Cartlidge M, Shuster S. Effect of L-dopa on the seborrhoea of Parkinsonism. Br J Dermatol. 1973, 88:475-9. 10.1111\/j.1365-2133.1973.tb15453.x","journal-title":"Br J Dermatol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1988.tb05386.x","article-title":"Incidence of seborrhoeic dermatitis in spinal injury patients","volume":"119","author":"Wilson CL","year":"1988","unstructured":"Wilson CL, Walshe M. Incidence of seborrhoeic dermatitis in spinal injury patients. Br J Dermatol. 1988, 119:48. 10.1111\/j.1365-2133.1988.tb05386.x","journal-title":"Br J Dermatol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10570.x","article-title":"Malassezia, dandruff and seborrhoeic dermatitis: an overview","volume":"165 Suppl 2","author":"Hay RJ","year":"2011","unstructured":"Hay RJ. Malassezia, dandruff and seborrhoeic dermatitis: an overview. Br J Dermatol. 2011, 165 Suppl 2:2-8. 10.1111\/j.1365-2133.2011.10570.x","journal-title":"Br J Dermatol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1956.01550020010002","article-title":"Unilateral seborrheic dermatitis following a nerve lesion","volume":"73","author":"BE FR","year":"1956","unstructured":"BE FR, MA RH. Unilateral seborrheic dermatitis following a nerve lesion. AMA Arch Derm. 1956, 73:110-5. 10.1001\/archderm.1956.01550020010002","journal-title":"AMA Arch Derm"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1990.tb08241.x","article-title":"The permissive effect of sebum in seborrhoeic dermatitis: an explanation of the rash in neurological disorders","volume":"122","author":"Cowley NC","year":"1990","unstructured":"Cowley NC, Farr PM, Shuster S. The permissive effect of sebum in seborrhoeic dermatitis: an explanation of the rash in neurological disorders. Br J Dermatol. 1990, 122:71-6. 10.1111\/j.1365-2133.1990.tb08241.x","journal-title":"Br J Dermatol"},{"key":"ref35","doi-asserted-by":"crossref","DOI":"10.2340\/0001555570432434","article-title":"Patients with mood depression have a high prevalence of seborrhoeic dermatitis","volume":"70","author":"Maietta G","year":"1990","unstructured":"Maietta G, Fornaro P, Rongioletti F, Rebora A. Patients with mood depression have a high prevalence of seborrhoeic dermatitis. Acta Derm Venereol. 1990, 70:432-4.","journal-title":"Acta Derm Venereol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1590\/s0365-05962011000600002","article-title":"Seborrheic dermatitis","volume":"86","author":"Sampaio AL","year":"2011","unstructured":"Sampaio AL, Mameri AC, Vargas TJ, Ramos-e-Silva M, Nunes AP, Carneiro SC. Seborrheic dermatitis. An Bras Dermatol. 2011, 86:1061-74. 10.1590\/s0365-05962011000600002","journal-title":"An Bras Dermatol"},{"key":"ref37","article-title":"Epidemiological studies of the influence of sunlight on the skin","volume":"6","author":"Berg M","year":"1989","unstructured":"Berg M. Epidemiological studies of the influence of sunlight on the skin. Photodermatol. 1989, 6:80-4.","journal-title":"Photodermatol"},{"key":"ref38","article-title":"Diagnosis and treatment of seborrheic dermatitis","volume":"91","author":"Clark GW","year":"2015","unstructured":"Clark GW, Pope SM, Jaboori KA. Diagnosis and treatment of seborrheic dermatitis. Am Fam Physician. 2015, 91:185-90.","journal-title":"Am Fam Physician"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/s0151-9638(07)92826-4","article-title":"Stress and seborrheic dermatitis (Article in French)","volume":"134","author":"Misery L","year":"2007","unstructured":"Misery L, Touboul S, Vin\u00e7ot C, et al.. Stress and seborrheic dermatitis (Article in French). Ann Dermatol Venereol. 2007, 134:833-7. 10.1016\/s0151-9638(07)92826-4","journal-title":"Ann Dermatol Venereol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2016.28.4.427","article-title":"Histopathological differential diagnosis of psoriasis and seborrheic dermatitis of the scalp","volume":"28","author":"Park JH","year":"2016","unstructured":"Park JH, Park YJ, Kim SK, et al.. Histopathological differential diagnosis of psoriasis and seborrheic dermatitis of the scalp. Ann Dermatol. 2016, 28:427-32. 10.5021\/ad.2016.28.4.427","journal-title":"Ann Dermatol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15157","article-title":"Prevalence, predictors and comorbidity of dry skin in the general population","volume":"33","author":"Augustin M","year":"2019","unstructured":"Augustin M, Kirsten N, K\u00f6rber A, et al.. Prevalence, predictors and comorbidity of dry skin in the general population. J Eur Acad Dermatol Venereol. 2019, 33:147-50. 10.1111\/jdv.15157","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref42","article-title":"Seborrheic dermatitis","author":"Tucker D","year":"2021","unstructured":"Tucker D, Masood S. Seborrheic dermatitis. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2021."},{"key":"ref43","article-title":"Comprehensive Dermatologic Drug Therapy E-Book, 3rd Ed","author":"Wu JJ","year":"2012","unstructured":"Wu JJ. Comprehensive Dermatologic Drug Therapy E-Book, 3rd Ed. Elsevier Saunders, Philadelphia, PA; 2012."},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1159\/000444682","article-title":"Treatment of seborrhoeic dermatitis in asia: a consensus guide","volume":"1","author":"Cheong WK","year":"2016","unstructured":"Cheong WK, Yeung CK, Torsekar RG, et al.. Treatment of seborrhoeic dermatitis in asia: a consensus guide. Skin Appendage Disord. 2016, 1:187-96. 10.1159\/000444682","journal-title":"Skin Appendage Disord"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1825","article-title":"Evidence-based Danish guidelines for the treatment of Malassezia-related skin diseases","volume":"95","author":"Hald M","year":"2015","unstructured":"Hald M, Arendrup MC, Svejgaard EL, Lindskov R, Foged EK, Saunte DM. Evidence-based Danish guidelines for the treatment of Malassezia-related skin diseases. Acta Derm Venereol. 2015, 95:12-9. 10.2340\/00015555-1825","journal-title":"Acta Derm Venereol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011380.pub2","article-title":"Interventions for infantile seborrhoeic dermatitis (including cradle cap)","volume":"3","author":"Victoire A","year":"2019","unstructured":"Victoire A, Magin P, Coughlan J, van Driel ML. Interventions for infantile seborrhoeic dermatitis (including cradle cap). Cochrane Database Syst Rev. 2019, 3:CD011380. 10.1002\/14651858.CD011380.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref47","article-title":"Use of topical corticosteroids in dermatology: an evidence-based approach","volume":"62","author":"Das A","year":"2017","unstructured":"Das A, Panda S. Use of topical corticosteroids in dermatology: an evidence-based approach. Indian J Dermatol. 2017, 62:237-50.","journal-title":"Indian J Dermatol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1080\/19381980.2017.1361573","article-title":"Cutaneous fungal microbiome: Malassezia yeasts in seborrheic dermatitis scalp in a randomized, comparative and therapeutic trial","volume":"9","author":"Kamamoto CS","year":"2017","unstructured":"Kamamoto CS, Nishikaku AS, Gompertz OF, Melo AS, Hassun KM, Bagatin E. Cutaneous fungal microbiome: Malassezia yeasts in seborrheic dermatitis scalp in a randomized, comparative and therapeutic trial. Dermatoendocrinol. 2017, 9:e1361573. 10.1080\/19381980.2017.1361573","journal-title":"Dermatoendocrinol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.0603a04","article-title":"Effect of itraconazole on the quality of life in patients with moderate to severe seborrheic dermatitis: a randomized, placebo-controlled trial","volume":"6","author":"Abbas Z","year":"2016","unstructured":"Abbas Z, Ghodsi SZ, Abedeni R. Effect of itraconazole on the quality of life in patients with moderate to severe seborrheic dermatitis: a randomized, placebo-controlled trial. Dermatol Pract Concept. 2016, 6:11-6. 10.5826\/dpc.0603a04","journal-title":"Dermatol Pract Concept"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12425","article-title":"The skin and Parkinson's disease: review of clinical, diagnostic, and therapeutic issues","volume":"4","author":"Skorvanek M","year":"2017","unstructured":"Skorvanek M, Bhatia KP. The skin and Parkinson's disease: review of clinical, diagnostic, and therapeutic issues. Mov Disord Clin Pract. 2017, 4:21-31. 10.1002\/mdc3.12425","journal-title":"Mov Disord Clin Pract"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1159\/000051628","article-title":"Effect of ketoconazole 1% and 2% shampoos on severe dandruff and seborrhoeic dermatitis: clinical, squamometric and mycological assessments","volume":"202","author":"Pi\u00e9rard-Franchimont C","year":"2001","unstructured":"Pi\u00e9rard-Franchimont C, Pi\u00e9rard GE, Arrese JE, De Doncker P. Effect of ketoconazole 1% and 2% shampoos on severe dandruff and seborrhoeic dermatitis: clinical, squamometric and mycological assessments. Dermatology. 2001, 202:171-6. 10.1159\/000051628","journal-title":"Dermatology"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1995.tb08680.x","article-title":"Successful treatment and prophylaxis of scalp seborrhoeic dermatitis and dandruff with 2% ketoconazole shampoo: results of a multicentre, double-blind, placebo-controlled trial","volume":"132","author":"Peter RU","year":"1995","unstructured":"Peter RU, Richarz-Barthauer U. Successful treatment and prophylaxis of scalp seborrhoeic dermatitis and dandruff with 2% ketoconazole shampoo: results of a multicentre, double-blind, placebo-controlled trial. Br J Dermatol. 1995, 132:441-5. 10.1111\/j.1365-2133.1995.tb08680.x","journal-title":"Br J Dermatol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1111\/j.1461-1244.2004.02382.x","article-title":"Rationale of frequency of use of ciclopirox 1% shampoo in the treatment of seborrheic dermatitis: results of a double-blind, placebo-controlled study comparing the efficacy of once, twice, and three times weekly usage","volume":"43 Suppl 1","author":"Abeck D","year":"2004","unstructured":"Abeck D. Rationale of frequency of use of ciclopirox 1% shampoo in the treatment of seborrheic dermatitis: results of a double-blind, placebo-controlled study comparing the efficacy of once, twice, and three times weekly usage. Int J Dermatol. 2004, 43 Suppl 1:13-6. 10.1111\/j.1461-1244.2004.02382.x","journal-title":"Int J Dermatol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1111\/j.1461-1244.2004.02409.x","article-title":"Safety and efficacy of ciclopirox 1% shampoo for the treatment of seborrheic dermatitis of the scalp in the US population: results of a double-blind, vehicle-controlled trial","volume":"43","author":"Lebwohl M","year":"2004","unstructured":"Lebwohl M, Plott T. Safety and efficacy of ciclopirox 1% shampoo for the treatment of seborrheic dermatitis of the scalp in the US population: results of a double-blind, vehicle-controlled trial. Int J Dermatol. 2004, 43:17-20. 10.1111\/j.1461-1244.2004.02409.x","journal-title":"Int J Dermatol"},{"key":"ref55","article-title":"Comprehensive Dermatologic Drug Therapy","author":"Wolverton SE","year":"2019","unstructured":"Wolverton SE. Comprehensive Dermatologic Drug Therapy. Wu JJ (ed): Elsevier, Amsterdam; 2019."},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04194.x","article-title":"Randomized, placebo-controlled, double-blind study on clinical efficacy of ciclopiroxolamine 1% cream in facial seborrhoeic dermatitis","volume":"144","author":"Dupuy P","year":"2001","unstructured":"Dupuy P, Maurette C, Amoric JC, Chosidow O. Randomized, placebo-controlled, double-blind study on clinical efficacy of ciclopiroxolamine 1% cream in facial seborrhoeic dermatitis. Br J Dermatol. 2001, 144:1033-7. 10.1046\/j.1365-2133.2001.04194.x","journal-title":"Br J Dermatol"},{"key":"ref57","article-title":"Treatment of Skin Disease: Comprehensive Therapeutic Strategies","author":"Lebwohl MG","year":"2013","unstructured":"Lebwohl MG, Heymann WR, Berth-Jones J, Coulson I. Treatment of Skin Disease: Comprehensive Therapeutic Strategies. Saunders (WB) Co Ltd, Edinburgh; 2013."},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2009.09.002","article-title":"An investigator-blind, randomized, 4-week, parallel-group, multicenter pilot study to compare the safety and efficacy of a nonsteroidal cream (Promiseb Topical Cream) and desonide cream 0.05% in the twice-daily treatment of mild to moderate seborrheic dermatitis of the face","volume":"27","author":"Elewski B","year":"2009","unstructured":"Elewski B. An investigator-blind, randomized, 4-week, parallel-group, multicenter pilot study to compare the safety and efficacy of a nonsteroidal cream (Promiseb Topical Cream) and desonide cream 0.05% in the twice-daily treatment of mild to moderate seborrheic dermatitis of the face. Clin Dermatol. 2009, 27:S48-53. 10.1016\/j.clindermatol.2009.09.002","journal-title":"Clin Dermatol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-015-0133-9","article-title":"Efficacy of oral itraconazole in the treatment and relapse prevention of moderate to severe seborrheic dermatitis: a randomized, placebo-controlled trial","volume":"16","author":"Ghodsi SZ","year":"2015","unstructured":"Ghodsi SZ, Abbas Z, Abedeni R. Efficacy of oral itraconazole in the treatment and relapse prevention of moderate to severe seborrheic dermatitis: a randomized, placebo-controlled trial. Am J Clin Dermatol. 2015, 16:431-7. 10.1007\/s40257-015-0133-9","journal-title":"Am J Clin Dermatol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12197","article-title":"Systematic review of oral treatments for seborrheic dermatitis","volume":"28","author":"Gupta AK","year":"2014","unstructured":"Gupta AK, Richardson M, Paquet M. Systematic review of oral treatments for seborrheic dermatitis. J Eur Acad Dermatol Venereol. 2014, 28:16-26. 10.1111\/jdv.12197","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.1999.00733.x","article-title":"Fluconazole vs. itraconazole in the treatment of tinea versicolor","volume":"38","author":"Montero-Gei F","year":"1999","unstructured":"Montero-Gei F, Robles ME, Suchil P. Fluconazole vs. itraconazole in the treatment of tinea versicolor. Int J Dermatol. 1999, 38:601-3. 10.1046\/j.1365-4362.1999.00733.x","journal-title":"Int J Dermatol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.1.69","article-title":"Efficacy of itraconazole in the prophylactic treatment of pityriasis (tinea) versicolor","volume":"138","author":"Faergemann J","year":"2002","unstructured":"Faergemann J, Gupta AK, Al Mofadi A, Abanami A, Shareaah AA, Marynissen G. Efficacy of itraconazole in the prophylactic treatment of pityriasis (tinea) versicolor. Arch Dermatol. 2002, 138:69-73. 10.1001\/archderm.138.1.69","journal-title":"Arch Dermatol"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.259","article-title":"Pityriasis versicolor: a systematic review of interventions","volume":"146","author":"Hu SW","year":"2010","unstructured":"Hu SW, Bigby M. Pityriasis versicolor: a systematic review of interventions. Arch Dermatol. 2010, 146:1132-40. 10.1001\/archdermatol.2010.259","journal-title":"Arch Dermatol"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2010.00908.x","article-title":"Single-dose oral fluconazole versus topical clotrimazole in patients with pityriasis versicolor: a double-blind randomized controlled trial","volume":"37","author":"Dehghan M","year":"2010","unstructured":"Dehghan M, Akbari N, Alborzi N, Sadani S, Keshtkar AA. Single-dose oral fluconazole versus topical clotrimazole in patients with pityriasis versicolor: a double-blind randomized controlled trial. J Dermatol. 2010, 37:699-702. 10.1111\/j.1346-8138.2010.00908.x","journal-title":"J Dermatol"},{"key":"ref65","article-title":"Calcineurin inhibitors","author":"Safarini OA","year":"2022","unstructured":"Safarini OA, Patel J. Calcineurin inhibitors. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2022."},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.5114\/pdia.2013.35619","article-title":"Topical calcineurin inhibitors in dermatology. Part I: properties, method and effectiveness of drug use","volume":"30","author":"Gutfreund K","year":"2013","unstructured":"Gutfreund K, Bienias W, Szewczyk A, Kaszuba A. Topical calcineurin inhibitors in dermatology. Part I: properties, method and effectiveness of drug use. Postepy Dermatol Alergol. 2013, 30:165-9. 10.5114\/pdia.2013.35619","journal-title":"Postepy Dermatol Alergol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/563709","article-title":"Clinical application of development of nonantibiotic macrolides that correct inflammation-driven immune dysfunction in inflammatory skin diseases","volume":"2012","author":"Rodriguez-Cerdeira C","year":"2012","unstructured":"Rodriguez-Cerdeira C, Sanchez-Blanco E, Molares-Vila A. Clinical application of development of nonantibiotic macrolides that correct inflammation-driven immune dysfunction in inflammatory skin diseases. Mediators Inflamm. 2012, 2012:563709. 10.1155\/2012\/563709","journal-title":"Mediators Inflamm"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.112600","article-title":"Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506)","volume":"107","author":"Panhans-Gross A","year":"2001","unstructured":"Panhans-Gross A, Novak N, Kraft S, Bieber T. Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506). J Allergy Clin Immunol. 2001, 107:345-52. 10.1067\/mai.2001.112600","journal-title":"J Allergy Clin Immunol"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1159\/000100884","article-title":"Comparative effect of tacrolimus and betamethasone valerate on the passive sustainable hydration of the stratum corneum in atopic dermatitis","volume":"214","author":"Xhauflaire-Uhoda E","year":"2007","unstructured":"Xhauflaire-Uhoda E, Thirion L, Pi\u00e9rard-Franchimont C, Pi\u00e9rard GE. Comparative effect of tacrolimus and betamethasone valerate on the passive sustainable hydration of the stratum corneum in atopic dermatitis. Dermatology. 2007, 214:328-32. 10.1159\/000100884","journal-title":"Dermatology"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200910020-00003","article-title":"Role of topical calcineurin inhibitors in the treatment of seborrheic dermatitis: a review of pathophysiology, safety, and efficacy","volume":"10","author":"Cook BA","year":"2009","unstructured":"Cook BA, Warshaw EM. Role of topical calcineurin inhibitors in the treatment of seborrheic dermatitis: a review of pathophysiology, safety, and efficacy. Am J Clin Dermatol. 2009, 10:103-18. 10.2165\/00128071-200910020-00003","journal-title":"Am J Clin Dermatol"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.9.1.69","article-title":"Ascomycins: promising agents for the treatment of inflammatory skin diseases","volume":"9","author":"Paul C","year":"2000","unstructured":"Paul C, Graeber M, Stuetz A. Ascomycins: promising agents for the treatment of inflammatory skin diseases. Expert Opin Investig Drugs. 2000, 9:69-77. 10.1517\/13543784.9.1.69","journal-title":"Expert Opin Investig Drugs"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.02974.x","article-title":"A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology","volume":"141","author":"Grassberger M","year":"1999","unstructured":"Grassberger M, Baumruker T, Enz A, et al.. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol. 1999, 141:264-73. 10.1046\/j.1365-2133.1999.02974.x","journal-title":"Br J Dermatol"},{"key":"ref73","article-title":"Pimecrolimus: a review of pre-clinical and clinical data","volume":"57","author":"Graham-Brown RA","year":"2003","unstructured":"Graham-Brown RA, Grassberger M. Pimecrolimus: a review of pre-clinical and clinical data. Int J Clin Pract. 2003, 57:319-27.","journal-title":"Int J Clin Pract"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1111\/j.0906-6705.2004.00269.x","article-title":"Pimecrolimus -- an anti-inflammatory drug targeting the skin","volume":"13","author":"Grassberger M","year":"2004","unstructured":"Grassberger M, Steinhoff M, Schneider D, Luger TA. Pimecrolimus -- an anti-inflammatory drug targeting the skin. Exp Dermatol. 2004, 13:721-30. 10.1111\/j.0906-6705.2004.00269.x","journal-title":"Exp Dermatol"},{"key":"ref75","article-title":"Pimecrolimus cream 1% can be an effective treatment for seborrheic dermatitis of the face and trunk","volume":"30","author":"Rallis E","year":"2004","unstructured":"Rallis E, Nasiopoulou A, Kouskoukis C, Koumantaki E. Pimecrolimus cream 1% can be an effective treatment for seborrheic dermatitis of the face and trunk. Drugs Exp Clin Res. 2004, 30:191-5.","journal-title":"Drugs Exp Clin Res"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.06208.x","article-title":"Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial","volume":"151","author":"Rigopoulos D","year":"2004","unstructured":"Rigopoulos D, Ioannides D, Kalogeromitros D, Gregoriou S, Katsambas A. Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial. Br J Dermatol. 2004, 151:1071-5. 10.1111\/j.1365-2133.2004.06208.x","journal-title":"Br J Dermatol"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.11.007","article-title":"Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis","volume":"57","author":"Warshaw EM","year":"2007","unstructured":"Warshaw EM, Wohlhuter RJ, Liu A, et al.. Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis. J Am Acad Dermatol. 2007, 57:257-64. 10.1016\/j.jaad.2006.11.007","journal-title":"J Am Acad Dermatol"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.8.1066","article-title":"Pimecrolimus cream, 1%, vs hydrocortisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: a randomized, investigator-blind, clinical trial","volume":"142","author":"Firooz A","year":"2006","unstructured":"Firooz A, Solhpour A, Gorouhi F, et al.. Pimecrolimus cream, 1%, vs hydrocortisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: a randomized, investigator-blind, clinical trial. Arch Dermatol. 2006, 142:1066-7. 10.1001\/archderm.142.8.1066","journal-title":"Arch Dermatol"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2006.01923.x","article-title":"An open-label efficacy pilot study with pimecrolimus cream 1% in adults with facial seborrhoeic dermatitis infected with HIV","volume":"21","author":"de Moraes AP","year":"2007","unstructured":"de Moraes AP, de Arruda EA, Vitoriano MA, de Moraes Filho MO, Bezerra FA, de Magalh\u00e3es Holanda E, de Moraes ME. An open-label efficacy pilot study with pimecrolimus cream 1% in adults with facial seborrhoeic dermatitis infected with HIV. J Eur Acad Dermatol Venereol. 2007, 21:596-601. 10.1111\/j.1468-3083.2006.01923.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref80","article-title":"Pimecrolimus: a new treatment for seborrheic dermatitis","volume":"70","author":"Crutchfield CE 3rd","year":"2002","unstructured":"Crutchfield CE 3rd. Pimecrolimus: a new treatment for seborrheic dermatitis. Cutis. 2002, 70:207-8.","journal-title":"Cutis"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1586\/ecp.11.68","article-title":"Pimecrolimus 1% cream for the treatment of seborrheic dermatitis: a systematic review of randomized controlled trials","volume":"5","author":"Ang-Tiu CU","year":"2012","unstructured":"Ang-Tiu CU, Meghrajani CF, Maano CC. Pimecrolimus 1% cream for the treatment of seborrheic dermatitis: a systematic review of randomized controlled trials. Expert Rev Clin Pharmacol. 2012, 5:91-7. 10.1586\/ecp.11.68","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref82","article-title":"Pimecrolimus for the Treatment of Adults with Atopic Dermatitis, Seborrheic Dermatitis, or Psoriasis: A Review of Clinical and Cost-Effectiveness [Internet]","author":"Deonandan R","year":"2017","unstructured":"Deonandan R, Severn M. Pimecrolimus for the Treatment of Adults with Atopic Dermatitis, Seborrheic Dermatitis, or Psoriasis: A Review of Clinical and Cost-Effectiveness [Internet]. Canadian Agency for Drugs and Technologies in Health, Ottawa; 2017."},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, et al.. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021, 372:n160. 10.1136\/bmj.n160","journal-title":"BMJ"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604","article-title":"","year":"2019","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (ed). Wiley-Blackwell, Hoboken, New Jersey, United States; 2019. 10.1002\/9781119536604"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani M","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016, 5:210. 10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness LA","year":"2021","unstructured":"McGuinness LA, Higgins JP. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021, 12:55-61. 10.1002\/jrsm.1411","journal-title":"Res Synth Methods"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwx344","article-title":"Association between risk-of-bias assessments and results of randomized trials in Cochrane reviews: the ROBES meta-epidemiologic study","volume":"187","author":"Savovic J","year":"2018","unstructured":"Savovic J, Turner RM, Mawdsley D, Jones HE, Beynon R, Higgins JP, Sterne JA. Association between risk-of-bias assessments and results of randomized trials in Cochrane reviews: the ROBES meta-epidemiologic study. Am J Epidemiol. 2018, 187:1113-22. 10.1093\/aje\/kwx344","journal-title":"Am J Epidemiol"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1080\/09546630802286993","article-title":"An open, randomized, prospective, comparative study of topical pimecrolimus 1% cream and topical ketoconazole 2% cream in the treatment of seborrheic dermatitis","volume":"20","author":"Koc E","year":"2009","unstructured":"Koc E, Arca E, Kose O, Akar A. An open, randomized, prospective, comparative study of topical pimecrolimus 1% cream and topical ketoconazole 2% cream in the treatment of seborrheic dermatitis. J Dermatolog Treat. 2009, 20:4-9. 10.1080\/09546630802286993","journal-title":"J Dermatolog Treat"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.3109\/09546630802687349","article-title":"Pimecrolimus 1% cream, methylprednisolone aceponate 0.1% cream and metronidazole 0.75% gel in the treatment of seborrhoeic dermatitis: a randomized clinical study","volume":"20","author":"Cicek D","year":"2009","unstructured":"Cicek D, Kandi B, Bakar S, Turgut D. Pimecrolimus 1% cream, methylprednisolone aceponate 0.1% cream and metronidazole 0.75% gel in the treatment of seborrhoeic dermatitis: a randomized clinical study. J Dermatolog Treat. 2009, 20:344-9. 10.3109\/09546630802687349","journal-title":"J Dermatolog Treat"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/101596-the-efficacy-and-safety-of-pimecrolimus-in-patients-with-facial-seborrheic-dermatitis-a-systematic-review-of-randomized-controlled-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:46:00Z","timestamp":1707507960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/101596-the-efficacy-and-safety-of-pimecrolimus-in-patients-with-facial-seborrheic-dermatitis-a-systematic-review-of-randomized-controlled-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,2]]},"references-count":89,"URL":"https:\/\/doi.org\/10.7759\/cureus.27622","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,2]]}}}